Advancing quality use of medicines in NSW

Fortnightly TAG Mail – resources list 11th April 2024

Open email discussions

- **1. Hospital-funded Shingrix**: Are DTCs receiving requests to approve use and funding of Shingrix in their immunocompromised patient populations that are outside the NIP criteria and what is your approach to these potentially very expensive requests? **Closes 24th April 2024**
- **2.** Hospital/district approaches to supplying and stocking COVID-19: Hospitals are requested to outline any strategies they are considering/implementing concerning supply of COVID-19 antivirals to ED patients and the stocking of COVID-19 antivirals for inpatient use. **Closes 1st May 2024**

Recently completed email discussions - link

- Handling of medicines by perfusionists
- DTC assessment process for non-GMO phage therapy applications
- DTC pharmacists in NSW
- Patient prioritisation for discharge medication list provision
- Missing medications from wards
- Medication reviews for inpatients in remote Multi-Purpose Services.

Upcoming TAG meetings

NSW TAG Editorial Committee Meeting: Monday 15th April 2024 11.00-12.30pm NSW TAG Management Committee 3rd May 2024 9.45am-11am

Updated TAG publications

Updated SGLT2 inhibitor Consumer Leaflet - link

Contact Sasha Bennett at <u>sasha.bennett@svha.org.au</u> for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AIM: - Management of Inpatient Elevated Blood Pressures - link

NHS England: Pharmacogenomics tutorial for pharmacists/pharmacy technicians - link

ISMP: Guardians of Grafts: Reducing Medication Errors in Transplant Recipients - link

BJCP: Assessing pain in persons with opioid use disorder: - link

BMJ Open: Implementation of an intervention aimed at deprescribing benzodiazepines in a large US healthcare system using patient education materials- $\underline{\text{link}}$

BMJQS: Estimating the impact on patient safety of enabling the digital transfer of patients' prescription information in the English NHS - link

Drug Safety: Drug-drug interactions and actual harm to hospitalized patients: a multicentre study examining the prevalence pre- and post-electronic medication system implementation - <u>link</u>

EHJ: Low-dose colchicine for atherosclerosis: long-term safety - link

EHJ: Use of new and emerging cancer drugs: what the cardiologist needs to know - link-

EJHP: Appropriateness of antithrombotics in geriatric inpatients with atrial fibrillation - link

HLC: Discharge Information About Adverse Drug Reactions Indicates Lower Self-Reported Adverse

Drug Reactions and Fewer Concerns in Patients After Percutaneous Coronary Intervention - <u>link</u> HTA: Evaluation of venous thromboembolism risk assessment models for hospital inpatients- <u>link</u>

IMJ: The increasing costs of medicines and their implications for patients, physicians and the health system - link

IJCP: Novel opportunities for clinical pharmacy research: development of a machine learning model to identify medication related causes of delirium in different patient groups - link

IJCP: Clinical pharmacy key performance indicators for hospital inpatient setting - link

JAGS: - Melatonin does not reduce delirium severity in hospitalized older adults - link

JAMA Network Open: Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia - link

JAMA Oncology: Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies - <u>link</u>

Lancet D&E: Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials— link

MJA: Editorial-Interventions for reducing the prescribing of pharmaceutical opioids in Australia: are they effectively reducing opioid harm? – <u>link</u> – and <u>research article</u>

NEJM: - Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 - <u>link</u> – <u>SPS</u> <u>commentary</u>

PEC: Medication Errors in Pediatric Emergency Departments - <u>link</u> Prescrire International: Prescrire's ratings of new drugs in 2023

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Launch of clinical care standard for psychotropic medicines - link

CATAG

Medicines Advice Initiative Australia (MAIA) project: Cumulative Medicines toolkit: Practice tool and Teaching tool - link

Collaborating with Consumers project: Understanding medicines access programs - link

NSW Health

- Measles alert for Western Sydney [31 March 2024] and factsheet
- Maintaining health during and after floods and storms link

TGA

- Update on the rescheduling of bromoxynil products - April 2024 - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found here

- Digital mental health interventions for young people evidence check - link

Australian Government Department of Health

- Unleashing the Potential of our Health Workforce - Scope of Practice Review - Issues Paper 1 - link

Australian Institute for Health and Welfare (AIHW)

- Australia's disability strategy 2021–2031 - link

MIMS monthly updates April 2024

- New Products
- -- Fezolinetant (<u>Veoza</u>) for moderate to severe vasomotor symptoms (VMS) associated with menopause
- -- Prasterone (<u>Intrarosa</u>) for vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms
- -- Recombinant respiratory syncytial virus pre-fusion F protein (RSVPreF3) vaccine (<u>Arexvy</u>) for active immunisation of individuals 60 years and older for the prevention of LRTD caused by RSV per official recommendations
- New Presentation
- -- Melatonin (Voquily) is now available as capsules and as an oral solution
- New Indications
- -- Empagliflozin (<u>Jardiance</u>) is now indicated to reduce the risk of kidney disease progression in adults with chronic kidney disease (CKD) stages 2 and 3A with urine albumin to creatinine ratio (UACR) ≥ 30 mg/g, or CKD stages 3B, 4 and 5 irrespective of UACR.
- -- Pembrolizumab (rch) (<u>Keytruda</u>) is now indicated as monotherapy for the adjuvant treatment of patients with Stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC who have undergone complete resection and platinum-based chemotherapy.

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

TGA

- <u>Database</u> of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
- -- Tibsovo (ivosidenib) for the treatment of acute myeloid leukaemia that carries a particular mutation

REPORTS AND PUBLICATIONS - INTERNATIONAL

Agency for Healthcare Research and Quality (AHRQ) USA

- Rapid Evidence Product: Prevention in Adults of Transmission of Infection With Multidrug-Resistant Organisms link
- Rapid Research: Failure To Rescue Rapid Response Systems link

Canadian Agency for Drugs and Technologies in Health

- Long-Term Use of Omalizumab for Chronic Idiopathic Urticaria - link

electronic Medicines Compendium (eMC) (UK)

- New products
- -- Ayvakyt (avapritinib) monotherapy for adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation
- -- Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide fumarate) new (lower) strength licensed for treatment of HIV without any known mutations linked to resistance to integrase inhibitor class, emtricitabine or tenofovir in patients aged from 2 years and with body weight ≥14 kg
- -- Povidone iodine 5% w/v eye drops solution for the pre-operative preparation of the surgical field (eyelids, lashes and cheeks) and irrigation of the ocular surface (cornea, conjunctiva and palpebral fornixes). Each 4ml single use container provides 200 mg of povidone iodine
- -- Rivaroxaban 2.5mg generic version licensed for use in combination with aspirin alone or aspirin + clopidogrel or ticlopidine, for prevention of atherothrombotic events after ACS with elevated cardiac biomarkers, or for CAD or symptomatic PAD at high risk of ischaemic events
- -- Velsipity (etrasimod) for patients aged ≥16 years with moderately to severely active ulcerative colitis who have had inadequate response, lost response, or were intolerant to either conventional therapy or a biological agent
- Revised SPCs
- -- DuoResp Spiromax (budesonide, formoterol) now also licensed for use as a reliever therapy for adults and adolescents (12 years and older) with mild asthma. The shelf-life after first opening has been extended from 6 months to 12 months
- -- Omeprazole new indication of the treatment of Zollinger-Ellison syndrome

Food and Drug Administration (FDA) USA

- FDA Approves First Prescription App for Depression link
- New Drug approvals
- -- Vafseo (vadadustat) to treat anemia due to chronic kidney disease
- -- Voydeya (danicopan) to treat extravascular haemolysis with paroxysmal nocturnal hemoglobinuria
- -- <u>Zevtera</u> (ceftobiprole medocaril sodium) to treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
- -- idecabtagene vicleucel (<u>Abecma</u>) CAR-T therapy approved for multiple myeloma after 2 or more lines of therapy
- New indications
- -- FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki (<u>Enhertu</u>) for unresectable or metastatic HER2-positive solid tumors
- -- iloperidone (<u>Fanapt</u>) for acute treatment of manic or mixed episodes associated with bipolar I disorder
- -- dolutegravir/lamivudine (Dovato) indication for HIV expanded to include adolescents
- -- ciltacabtagene autoleucel (<u>Carvykti</u>) earlier treatment approved for multiple myeloma after 1 or more lines of therapy

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Medicines and Healthcare products Regulatory Agency (MHRA)

- MHRA approves combined antibiotic cefepime/enmetazobactam (Exblifep 2g/0.5 g powder for concentrate for solution for infusion) link
- Fosdenopterin approved to treat adult patients with molybdenum cofactor deficiency (MoCD) Type A
- link

NHS England

- Medicines Learning Portal: Pharmacogenomics tutorial for pharmacists/pharmacy technicians link
- Quality & outcomes framework guidance for 2024/25, including new cholesterol indicator (CHOL004)

NHS Scotland/Scottish Medicines Consortium

- Accepted for use:
- -- <u>dostarlimab</u> (Jemperli) in combination with platinum-containing chemotherapy for patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer
- -- mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy
- -- ritlecitinib (Litfulo) for severe alopecia areata in adults and adolescents 12 years of age and older
- Accepted for restricted use:
- -- <u>daridorexant</u> (Quviviq) for adult insomnia patients with symptoms present for at least 3 months whose daytime functioning is impacted
- -- <u>tirzepatide</u> (Mounjaro) for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

National Institute for Health and Care Excellence (NICE) UK

- Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)
- Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)
- Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)
- Twin and triplet pregnancy- updated guidance (NG137)
- Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

National Institute for Health and Care Research (NIHR)

- Irritable bowel syndrome: low-dose antidepressant improves symptoms link
- Surgery is better than nasal sprays for people with severely blocked airways link

Scottish Intercollegiate Guideline Network (SIGN) UK

- SIGN170 Optimising glycaemic control in people with type 1 diabetes - link - toolkit

Specialist Pharmacy Services NHS UK

- Understanding complementary medicines - link

UK Health Security Agency

- National criteria for prompt intravenous-to-oral switch (IVOS) of antimicrobials in children and young people (including newborns) - <u>link</u> – <u>SPS commentary</u>

World Health Organisation (WHO)

- Consolidated guidelines on person-centred viral hepatitis strategic information: using data to support country scale-up of hepatitis prevention, diagnosis and treatment services Link
- Co-administration of treatment for drug-resistant tuberculosis and hepatitis C: rapid communication link
- WHO publishes new guidelines on hepatitis B link
- WHO launches guidance on conducting reviews of tuberculosis programmes link
- WHO unveils a digital health promoter harnessing generative AI for public health link
- Telehealth quality of care tool link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

MEDICATION SAFETY

All Wales Therapeutics and Toxicology Centre

- The All Wales Policy for Medicines Administration, Recording, Review, Storage & Disposal (<u>Update</u>)

electronic Medicines Compendium (eMC) (UK)

- Revised SPCs
- -- Benlysta (belimumab) frequency of ADRs urticaria and rash from 'uncommon' to 'common', and diarrhoea and nausea from 'verv common' to 'common'
- -- Bonviva (ibandronic acid) atypical fractures of long bones other than the femur added as a potential ADR of treatment (frequency unknown). These fractures occur after minimal, or no trauma and some patients experience prodromal pain prior to presenting with a completed fracture
- -- Copaxone (glatiramer) moderate amount of data (300-1000 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity, & animal studies do not indicate reproductive toxicity. Manufacturers advise use may be considered during pregnancy, if necessary
- -- Dalacin (clindamycin) risk of the known possible adverse effect of oesophagitis and oesophageal ulcer is increased if taken in a lying position and/or with a small amount of water
- -- Edronax (Reboxetine) serotonin syndrome included as possible ADR, frequency 'not known'
- -- Elvanse Adult (lisdexamfetamine) epistaxis added as potential ADR of uncommon frequency
- -- Equasym (methylphenidate) contusion added as ADR of unknown frequency
- -- Eylea (aflibercept) unopened vial may be stored outside refrigerator below 25 °C for up to 24 hrs
- -- Gavreto (pralsetinib) male patients with female partners of childbearing potential must use effective contraception, including a barrier method during treatment with pralsetinib and for at least 1 week following the last dose of treatment
- -- Lemsip Cough for Mucus Cough & Catarrh (guaifenesin & cetylpyridinium chloride) contraindicated in children under 6 years. Caution is use is also advised in patients with porphyria
- -- Matrifen (fentanyl) transdermal dysphagia added as uncommon potential ADR
- -- Mektovi (binimetinib) occurrence of tumour lysis syndrome, which may be fatal, has been linked to use of binimetinib in association with encorafenib. Risk factors include high tumour burden, pre-existing chronic renal insufficiency, oliquria, dehydration, hypotension and acidic urine
- -- Neupogen (filgrastim) extramedullary haematopoeisis added as ADR of rare frequency
- -- Ninlaro (ixazomib citrate) rare ADRs added: toxic epidermal necrolysis (TEN), anaphylactic reaction, and angioedema. Further warning and precaution information on TEN is also detailed
- -- Nortriptyline unmasking of Brugada syndrome has been reported with nortriptyline. Nortriptyline should generally be avoided in patients with or suspected of having Brugada syndrome. Risk factors for Brugada syndrome include a family history of cardiac arrest or sudden death
- -- Ontozry (cenobamate) suicidal ideation and behaviour have been reported in patients treated with anti-epileptic medicinal products including cenobamate (uncommon frequency)
- -- Questran and Questran Light (colestyramine) info added on concomitant use with a statin, avoiding use in patients with exudative/bloody diarrhoea, timing of administration in relation to absorption of other drugs, risk of constipation or its aggravation, and drug interactions with digoxin and spironolactone
- -- Remsima (infliximab) the period in which administration of live vaccines to infants exposed to infliximab in utero is not recommended has been extended from 6 months to 12 months, after birth. Additionally, dyslipidaemia has been added as an uncommon ADR
- -- Sodium Oxybate shelf-life for unopened product has been changed from 3 to 5 years, and shelf-life after first opening has been changed from 40 to 90 days
- -- Sutent (sunitinib) hyperammonemic encephalopathy added as a potential ADR of treatment (unknown frequency). In patients who develop unexplained lethargy or changes in mental status, ammonia level should be measured and appropriate clinical management should be initiated
- -- Upstaza (eladocagene exuparvovec) feeding disorders included as a possible 'common' ADR, frequencies of irritability changed from 'very common' to 'common' and decubitus ulcer from 'common' to 'very common', paragraph included about cerebrospinal fluid leaks
- -- Zelboraf (vemurafenib) stomatitis added as a common potential ADR of treatment
- Risk minimisation materials
- -- Farydak (<u>Panobinostat</u>) patient cards for cycles 1-8 and 9-16 are intended to help patients keep track of their treatment regimen and maintain compliance

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Institute for Safe Medication Practices (ISMP) USA

- Medication Safety Alert! April 4, 2024 including: Look-alike vials of Adrenalin and Retacrit
- -- Guardians of Grafts: Reducing Medication Errors in Transplant Recipients link

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- - National Patient Safety Alert: Reducing risks for transfusion-associated circulatory overload link
- Drug Safety Update March 2024
- -- Pseudoephedrine Risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) link

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Calcium channel blockers and the possible risk of new-onset eczema - link

MIMS monthly updates April 2024

- New Contraindications
- -- Morphine sulfate pentahydrate (<u>DBL Morphine Sulfate Injection</u>) is now contraindicated in respiratory failure; bronchial asthma or other obstructive airways disease (regardless of disease duration, severity); emphysema (any severity); severe depressed level of consciousness; diabetic ketoacidosis; and alcoholism or delirium tremens (regardless of disease duration).
- -- Nirmatrelvir and ritonavir (<u>Paxlovid</u>) is now contraindicated for concomitant use with sildenafil when used for pulmonary hypertension; avanafil and vardenafil when used for erectile dysfunction; and zolpidem.

Specialist Pharmacy Services NHS UK

- Using tetracycline antibiotics during breastfeeding link
- Calculating kidney function link

TGA

- Update on the shortage of Bicillin L-A (benzathine benzylpenicillin tetrahydrate) prefilled syringe for injection <u>link</u>
- Substandard semaglutide vials link

PAPERS OF INTEREST

American Journal of Cardiology

- Atrial Thrombosis Prevalence Before Cardioversion or Catheter Ablation of Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists link
- Cardiovascular Outcomes with Empagliflozin and Dapagliflozin in Patients Without Diabetes link

American Journal of Gastroenterology

- Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis - link

American Journal of Health-System Pharmacy (AJHP)

- Evaluation of pharmacy-supplied half and quarter tablets at an academic medical center link
- Impact of a calcium replacement protocol during massive transfusion in trauma patients at a level 2 trauma center $\underline{\text{link}}$
- Integration of electronic project management software in an investigational drug service pharmacy within an academic medical center link
- Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system $\underline{\text{link}}$

Annals of Emergency Medicine

- Topical Diclofenac Versus Oral Ibuprofen Versus Diclofenac + Ibuprofen for Emergency Department Patients with Acute Low Back Pain: A Randomized Study $-\frac{link}{link}$

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Annals of Internal Medicine

- Management of Inpatient Elevated Blood Pressures: A Systematic Review of Clinical Practice Guidelines <u>link</u>
- Long-Term Effect of Salt Substitution for Cardiovascular Outcomes: A Systematic Review and Meta-Analysis $\underline{\text{link}}$

Arthritis & Rheumatology

- Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: Results from a head-to-head randomized phase IIIb study - link

British Journal of Clinical Pharmacology

- Assessing pain in persons with opioid use disorder: Approaches, techniques and special considerations link
- Association between reversal agents (sugammadex vs. neostigmine) for neuromuscular block and postoperative pulmonary complications: A retrospective analysis link
- OpenSAFELY: The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate link

British Journal of General Practice

- Prednisolone in COPD: the overlooked harm - link

British Medical Journal (BMJ)

- Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study link
- Use of progestogens and the risk of intracranial meningioma: national case-control study link
- Practice pointer: Group A beta-haemolytic streptococcal infection in children link
- Quantifying possible bias in clinical and epidemiological studies with quantitative bias analysis: common approaches and limitations $\underline{\text{link}}$

BMJ Open

- Implementation of an intervention aimed at deprescribing benzodiazepines in a large US healthcare system using patient education materials: a pre/post-observational study with a control group - link

BMJ Quality and Safety

- Estimating the impact on patient safety of enabling the digital transfer of patients' prescription information in the English NHS - link

Circulation

- Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis <u>link</u>
- Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial <u>link</u>
- A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy with A Fully Magnetically Levitated LVAD: The DOT-HM3 Study link
- Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial <a href="https://link.org/link.o

Cochrane

- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women link
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants link

Diabetes Care

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting link
- Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use link
- Timing of Moderate to Vigorous Physical Activity, Mortality, Cardiovascular Disease, and Microvascular Disease in Adults With Obesity $\underline{\mathsf{link}}$

Drug and Therapeutics Bulletin

- DTB Select: Donanemab in early symptomatic Alzheimer's disease link
- Medicines and global warming: a complex problem link

Drug Safety

- Drug-drug interactions and actual harm to hospitalized patients: a multicentre study examining the prevalence pre- and post-electronic medication system implementation - link

European Heart Journal

- Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial link
- Low-dose colchicine for atherosclerosis: long-term safety link
- Use of new and emerging cancer drugs: what the cardiologist needs to know link

European Journal of Hospital Pharmacy

- Appropriateness of antithrombotics in geriatric inpatients with atrial fibrillation: a retrospective, cross-sectional study link
- Haemodynamic effects of intravenous acetaminophen in critically ill paediatric patients: a retrospective chart review link

Health Technology Assessment

- Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis <u>link</u>
- Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study <u>link</u>

Heart, Lung and Circulation

- Discharge Information About Adverse Drug Reactions Indicates Lower Self-Reported Adverse Drug Reactions and Fewer Concerns in Patients After Percutaneous Coronary Intervention - <u>link</u>

Hospital Pediatrics

- Decreasing prescribing errors in antimicrobial stewardship program-restricted medications - link

Internal Medicine Journal

- The increasing costs of medicines and their implications for patients, physicians and the health system - link

International Journal of Clinical Pharmacy

- Novel opportunities for clinical pharmacy research: development of a machine learning model to identify medication related causes of delirium in different patient groups $\underline{\text{link}}$
- Clinical pharmacy key performance indicators for hospital inpatient setting: a systematic review link

JAMA

- Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability $\underline{\mathsf{link}} \underline{\mathsf{SPS}}$ commentary
- Risk Assessment and Prevention of Falls in Older Community-Dwelling Adults: A Review link
- Common Oral Conditions: A Review link
- Reducing Hospitalizations and Multidrug-Resistant Organisms via Regional Decolonization in Hospitals and Nursing Homes <u>link</u> <u>SPS commentary</u>

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- Integrated Hepatitis C–Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial link
- Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval link
- JAMA Patient Page: I Read Health Information Online—Can I Trust It? link
- Systemic Lupus Erythematosus: A Review link
- Mortality Among Users of Anabolic Steroids link

JAMA Cardiology

- Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis link
- Influenza Vaccine Immune Response in Patients with High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial link
- Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial link

JAMA Dermatology

- Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole–Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis link SPS commentary
- Emergency Contraception for Patients Taking Isotretinoin link

JAMA Internal Medicine

- d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial - <u>link</u>

JAMA Network Open

- Estimated Sustainable Cost-Based Prices for Diabetes Medicines link
- Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia link

JAMA Neurology

- Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders <u>link</u>
- Early Seizure Prophylaxis in Mild and Moderate Traumatic Brain Injury: A Systematic Review and Meta-Analysis <u>link</u>

JAMA Oncology

- Patient Page: Cancer Care in the Era of Artificial Intelligence link
- Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies link

Journal of the American Geriatrics Society

- Melatonin does not reduce delirium severity in hospitalized older adults: Results of a randomized placebo-controlled trial - <u>link</u>

Journal of the American College of Cardiology

- Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI link
- Association of Antiarrhythmic Drug Therapy With Syncope and Pacemaker Implantation in Patients With Atrial Fibrillation link
- Efficacy and Safety of Dapagliflozin in Patients with Acute Heart Failure link

Journal of Infection

- Within-episode repeat antibiotic prescriptions in patients with respiratory tract infections: A population-based cohort study - \underline{link}

Journal of the National Cancer Institute

- Association of metformin use and cancer incidence: a systematic review and meta-analysis - link

Journal of Pharmacy Practice and Research (JPPR)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

An initiative of Now Chilical pharmacologists & pharmacists

- Risk of Pseudomonas aeruginosa antimicrobial resistance using time series analysis of antibiotic usage - link

Lancet

- Valvular heart disease: from mechanisms to management link
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network metaanalysis of randomised controlled trials - <u>link</u>
- Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial link

Lancet Diabetes & Endocrinology

- Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis <u>link</u> <u>SPS</u> commentary
- Endocrine health in survivors of adult-onset cancer link

Lancet Respiratory Medicine

- High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial - link

Molecular Diversity Preservation International (MDPI) - Pharmacy Journal

- Association of Average Daily Morphine Milligram Equivalents and Falls in Older Adult Chronic Opioid Users link
- Evolution of Telehealth—Its Impact on Palliative Care and Medication Management link
- Evaluation of Oral Amoxicillin/Clavulanate for Urinary Tract Infections Caused by Ceftriaxone Non-Susceptible Enterobacterales \underline{link}

Medical Journal of Australia

- Australian consensus statement on doxycycline post-exposure prophylaxis (doxy-PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men link and response
- Editorial: Interventions for reducing the prescribing of pharmaceutical opioids in Australia: are they effectively reducing opioid harm? link and research article
- The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019–2022: longitudinal sales data analysis <u>link</u>

New England Journal of Medicine

- Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 <u>link</u> <u>SPS</u> commentary
- Prevention of Cardiovascular Disease in Type 1 Diabetes link
- Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction link
- Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction link
- Empagliflozin after Acute Myocardial Infarction <u>link</u> <u>SPS commentary</u>
- Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk link
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes link

Pediatric Emergency Care

- Medication Errors in Pediatric Emergency Departments: A Systematic Review and Recommendations for Enhancing Medication Safety - $\underline{\text{link}}$

Pharmacotherapy

- Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy link
- Vancomycin AUC0–24 estimation using first-order pharmacokinetic methods in pediatric patients $\underline{\text{link}}$

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Prescrire International - April 2024 issue including:

- Editorial: Evaluating drugs for today's patients, without neglecting tomorrow's patients link
- GLP-1 agonists: depression, suicidal thoughts or behaviour?
- RSVpreF vaccine (Abrysvo°) during pregnancy to prevent RSV infection in the woman's child after birth
- Prescrire's ratings of new drugs in 2023

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- Episode 161 - Managing hypercholesterolaemia

MJA Podcasts

- Episode 11: Pregnancy supplements how much is too much?
- Episode 10: How GPs can help women improve their self-compassion and reduce depression

Victorian Institute of Forensic Medicine

- Residential Aged Care Communiqué Episode #17: Diabetes mellitus - link

UPCOMING EVENTS

AHHA

- Webinar: Advancing VBHC in Australia: Lessons from the NHS Wales, online, 2 May 2024 12:30-13:30 register
- Post-Budget Health Leaders Roundtable, Canberra, 17 May 2024 10:00-16:00 register

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists